---
title: 'CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage
  switch and slow early response to treatment'
date: '2024-01-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38215390/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240113170706&v=2.18.0
source: Blood
description: In the effort to improve immunophenotyping and minimal residual disease
  (MRD) assessment in acute lymphoblastic leukemia (ALL), the international Berlin-Frankfurt-Münster
  (iBFM) Flow Network introduced the myelomonocytic marker CD371 in 2014, for a large
  prospective characterization with a long follow-up. In the present study, we aimed
  to investigate the clinical and biological features of CD371-positive (CD371pos)
  pediatric BCP-ALL. From June 2014 to February 2017, 1812 pediatric patients ...
disable_comments: true
---
In the effort to improve immunophenotyping and minimal residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL), the international Berlin-Frankfurt-Münster (iBFM) Flow Network introduced the myelomonocytic marker CD371 in 2014, for a large prospective characterization with a long follow-up. In the present study, we aimed to investigate the clinical and biological features of CD371-positive (CD371pos) pediatric BCP-ALL. From June 2014 to February 2017, 1812 pediatric patients ...